Combining stat3-targeting agents with immune checkpoint inhibitors in nsclc

HIGHLIGHTS

SUMMARY

Lung cancer is one of the most aggressive cancers and is responsible for the majority of cancer deaths worldwide. In NSCLC, STAT3 activation within cancer or immune cells favors an immunosuppressive tumor microenvironment and supports an inflammatory state that promotes tumor growth. In the lung, when STAT3 is aberrantly activated within myeloid cells, it promotes the development of cancer by recruiting the tumor microenvironment immune cells that have immunosuppressive functions. Of note, in_vivo data showed that STAT3 knockdown reversed this resistance, implying that STAT3-targeting, together with immune checkpoint inhibitors, is a viable pharmacological . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.